The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism

NCT00451672 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2007-03-23

No results posted yet for this study

Summary

we propose that bromocriptine may be an alternative treatment of primary aldosteronism, both APA and BAH.

Conditions

Interventions

DRUG

bromocriptine

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Kwan-Dun Wu, MD, PhD · Internal Medicine, Natinal Taiwan University Hospital

  • Vin-Cent Wu, MD · Internal Medicine, National Taiwan University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Completion
2007-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00451672 on ClinicalTrials.gov